Medicine
Sutab 2.7 g/2.25 g/17.75 g tablet
Sutab 2.7 g/2.25 g/17.75 g tablet is a prescription medicine containing Magnesium sulfate, Potassium chloride and Sodium sulfate for oral use, marketed by Azurity Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20º to 25°C (68º to 77°F). Excursions permitted between 15º to 30°C…
Key facts
- Active ingredient (INN)
- Magnesium sulfate, Potassium chloride and Sodium sulfate
- Brand
- Sutab
- Strength
- 2.7 g/2.25 g/17.75 g
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 2 bottles
- Marketing authorisation holder
- Azurity Pharmaceuticals
- Manufacturers
- Azurity PharmaceuticalsBraintree Laboratories
- Origin register
- US FDA, United States
- Storage
- Store at 20º to 25°C (68º to 77°F). Excursions permitted between 15º to 30°C (59º to 86°F). See USP controlled room temperature.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 November 2020
- Identifiers
- DailyMed set ID dddd2701-4d46-44de-a9f8-303d4dcceef7, c020e973-dccf-4862-999e-17db6209a48aNDC 52268-201, 24338-201Application NDA213135
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 bottle, plastic in 1 kit / 12 tablet in 1 bottle, plastic | 24338-201-01 | Azurity Pharmaceuticals | 1 April 2026 |
| 2 bottle, plastic in 1 kit / 12 tablet in 1 bottle, plastic | 52268-201-01 | Braintree Laboratories | 10 November 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 November 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Magnesium sulfate, Potassium chloride and Sodium sulfate is a fixed-dose combination of an osmotic laxative, a calculi dissolution agent and a potassium salt. It is available as tablets for oral use. MedsAcross supplies Magnesium sulfate, Potassium chloride and Sodium sulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Magnesium sulfate, Potassium chloride and Sodium sulfateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SUTAB prescribing information (Braintree Laboratories) · U.S. National Library of Medicine, DailyMed
Need Sutab 2.7 g/2.25 g/17.75 g tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.